
Kazia Therapeutics Limited KZIA
€ 10.75
0.08%
Quartalsbericht 2026-Q2
hinzugefügt 16.05.2026
Kazia Therapeutics Limited Betriebsaufwand 2011-2026 | KZIA
Betriebsaufwand Jährlich Kazia Therapeutics Limited
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | 8.82 M | 12.5 M | 10.4 M | 12.8 M | 8.14 M | 6.4 M | 3.11 M | 11.2 M | 13.5 M |
Alle Zahlen in AUD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 13.5 M | 3.11 M | 9.64 M |
Betriebsaufwand anderer Aktien in der Pharmaeinzelhändler
| Name | Betriebsaufwand | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
|
FSD Pharma
HUGE
|
15.3 M | - | 5743.5 % | $ 69.7 M | ||
|
MorphoSys AG
MOR
|
432 M | - | 2.43 % | $ 254 M | ||
|
Happiness Biotech Group Limited
HAPP
|
6.79 M | - | 1.35 % | $ 17.8 M | ||
|
AgeX Therapeutics
AGE
|
24.2 M | - | -10.17 % | $ 12.2 K | ||
|
Coherus BioSciences
CHRS
|
231 M | $ 1.73 | 5.18 % | $ 203 M | ||
|
I-Mab
IMAB
|
1.49 B | - | - | $ 866 M | ||
|
Celldex Therapeutics
CLDX
|
58.1 M | $ 31.65 | 2.59 % | $ 2.1 B | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
2.66 B | - | - | $ 40.3 B | ||
|
Genfit SA
GNFT
|
78.3 M | - | 2.54 % | $ 160 B | ||
|
BioNTech SE
BNTX
|
512 M | $ 94.81 | 2.78 % | $ 22.9 B | ||
|
AstraZeneca PLC
AZN
|
17.6 B | - | - | $ 96.9 B | ||
|
CRISPR Therapeutics AG
CRSP
|
668 M | $ 53.52 | 3.74 % | $ 4.81 B | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
8.22 M | - | -1.52 % | $ 24.7 M | ||
|
Athira Pharma
ATHA
|
18.7 M | - | - | $ 269 M | ||
|
BiondVax Pharmaceuticals Ltd.
BVXV
|
78.4 M | - | 0.74 % | $ 768 M | ||
|
Compugen Ltd.
CGEN
|
32.2 M | $ 2.68 | 1.13 % | $ 250 M | ||
|
Abcam plc
ABCM
|
170 M | - | - | $ 4.9 B | ||
|
Galera Therapeutics
GRTX
|
70.6 M | - | -32.59 % | $ 7.61 M | ||
|
Midatech Pharma plc
MTP
|
4.78 M | - | -18.52 % | $ 27.3 M | ||
|
Enlivex Therapeutics Ltd.
ENLV
|
15 M | $ 0.78 | 14.04 % | $ 35.6 M | ||
|
Esperion Therapeutics
ESPR
|
343 M | $ 3.13 | 0.32 % | $ 651 M | ||
|
Eton Pharmaceuticals
ETON
|
43.6 M | $ 31.66 | 1.18 % | $ 852 M | ||
|
Affimed N.V.
AFMD
|
54 M | - | -34.95 % | $ 21.5 M | ||
|
Forte Biosciences
FBRX
|
70.7 M | $ 22.13 | 0.87 % | $ 287 M | ||
|
Институт стволовых клеток человека
ISKJ
|
629 M | - | - | - | ||
|
Checkmate Pharmaceuticals
CMPI
|
61.5 M | - | - | $ 231 M | ||
|
Celyad Oncology SA
CYAD
|
26.2 M | - | - | $ 12.5 M | ||
|
Berkeley Lights
BLI
|
152 M | - | -7.31 % | $ 87 M | ||
|
Galectin Therapeutics
GALT
|
20.1 M | $ 2.72 | -2.69 % | $ 174 M | ||
|
Generation Bio Co.
GBIO
|
162 M | - | - | $ 344 M | ||
|
IMV
IMV
|
35.1 M | - | - | $ 13.1 M | ||
|
Akero Therapeutics
AKRO
|
80.2 M | - | - | $ 3.67 B | ||
|
Akouos
AKUS
|
86.8 M | - | 0.23 % | $ 488 M | ||
|
Ayala Pharmaceuticals
AYLA
|
29.8 M | - | - | $ 7.46 M | ||
|
Grifols, S.A.
GRFS
|
1.64 B | $ 8.08 | 0.9 % | $ 5.49 B | ||
|
Hutchison China MediTech Limited
HCM
|
236 M | $ 11.72 | -0.26 % | $ 10.1 B | ||
|
Cyclacel Pharmaceuticals
CYCCP
|
9.17 M | - | -4.36 % | $ 27 M | ||
|
Freeline Therapeutics Holdings plc
FRLN
|
98.4 M | - | - | $ 384 M | ||
|
Heron Therapeutics
HRTX
|
281 M | $ 0.9 | 2.13 % | $ 150 M | ||
|
Gracell Biotechnologies
GRCL
|
214 M | - | - | $ 3.37 B | ||
|
Anika Therapeutics
ANIK
|
51.6 M | $ 14.76 | -0.87 % | $ 212 M | ||
|
Advaxis
ADXS
|
19.6 M | - | -9.65 % | $ 45.9 M | ||
|
Aeterna Zentaris
AEZS
|
13.3 M | - | 5.93 % | $ 314 M | ||
|
InflaRx N.V.
IFRX
|
52.4 M | $ 2.6 | -5.11 % | $ 175 M | ||
|
Aeglea BioTherapeutics
AGLE
|
210 M | - | - | $ 1.01 B | ||
|
CureVac N.V.
CVAC
|
88.9 M | - | - | $ 867 M | ||
|
Applied Genetic Technologies Corporation
AGTC
|
66.5 M | - | - | $ 26.5 M | ||
|
AIkido Pharma
AIKI
|
179 M | - | 1.93 % | $ 17.4 M | ||
|
Can-Fite BioPharma Ltd.
CANF
|
10.4 M | $ 3.35 | -4.83 % | $ 5.51 M |